US EditionAnaptysBio (NASDAQ:ANAB) Receives Buy Rating from Guggenheim
Summary by watchlistnews.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
AnaptysBio (NASDAQ:ANAB) Receives Buy Rating from Guggenheim
Guggenheim reiterated their buy rating on shares of AnaptysBio (NASDAQ:ANAB – Free Report) in a research note released on Wednesday, MarketBeat reports. The brokerage currently has a $90.00 target price on the biotechnology company’s stock, up from their prior target price of $54.00. Several other equities research analysts also recently weighed in on ANAB. Wolfe […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
